Phase II study of m-AMSA in advances malignant melanoma
A phase II study of methanesulfonamide, N-(4-(9 acridinylamino)-3-methoxyphenyl)-(m-AMSA) was undertaken by the Eastern Cooperative Oncology Group. Thirty-five evaluable patients were studied, 18 of whom had had no prior therapy and eight of whom had been treated only one cytotoxic drug. Thirty-one...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical oncology 1982-08, Vol.5 (4), p.433 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 433 |
| container_title | American journal of clinical oncology |
| container_volume | 5 |
| creator | Arseneau, J C Wolter, J M Probert, J C Kuperminc, M |
| description | A phase II study of methanesulfonamide, N-(4-(9 acridinylamino)-3-methoxyphenyl)-(m-AMSA) was undertaken by the Eastern Cooperative Oncology Group. Thirty-five evaluable patients were studied, 18 of whom had had no prior therapy and eight of whom had been treated only one cytotoxic drug. Thirty-one of these patients were ECOG performance status 2 or better. The dose of m-AMSA employed in this study was 40 mg/M2 as an I.V. infusion over 20 minutes daily for 3 days, repeated every 3 weeks. Leukopenia was found to be dose-limiting; thrombocytopenia and anemia were also observed. Other prominent toxicities included anorexia, nausea, and vomiting. No cardiovascular toxicity was observed in this study, but none of the patients had received prior anthracycline therapy. Only one partial response of measurable disease was observed, all other patients had progressive disease on m-AMSA therapy. No significant clinical activity of m-AMSA against malignant melanoma was demonstrated in this very favorable group of patients. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_6896795</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>6896795</sourcerecordid><originalsourceid>FETCH-LOGICAL-p535-944da0e7d046efb43840be85a70223785b0f1e6f85a0a3efc52852025b687e623</originalsourceid><addsrcrecordid>eNotjstKAzEUQLNQaq1-gpAfCFzzupnlUHwMtCjYfblpbnRkMh2aVujfK9jVgbM4nCsxB42oDBp9I25r_QYA5wFnYuZD47Fxc4HvX1RZdp2sx1M6y32WRbXrj1b2o6T0Q-OOqyw09J8jjUdZeKBxX-hOXGcaKt9fuBCb56fN8lWt3l66ZbtSkzNONdYmAsYE1nOO1gQLkYMjBK0NBhchP7LPfwbIcN45HZwG7aIPyF6bhXj4z06nWDhtp0Nf6HDeXv7NL-G-PkU</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase II study of m-AMSA in advances malignant melanoma</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Arseneau, J C ; Wolter, J M ; Probert, J C ; Kuperminc, M</creator><creatorcontrib>Arseneau, J C ; Wolter, J M ; Probert, J C ; Kuperminc, M</creatorcontrib><description>A phase II study of methanesulfonamide, N-(4-(9 acridinylamino)-3-methoxyphenyl)-(m-AMSA) was undertaken by the Eastern Cooperative Oncology Group. Thirty-five evaluable patients were studied, 18 of whom had had no prior therapy and eight of whom had been treated only one cytotoxic drug. Thirty-one of these patients were ECOG performance status 2 or better. The dose of m-AMSA employed in this study was 40 mg/M2 as an I.V. infusion over 20 minutes daily for 3 days, repeated every 3 weeks. Leukopenia was found to be dose-limiting; thrombocytopenia and anemia were also observed. Other prominent toxicities included anorexia, nausea, and vomiting. No cardiovascular toxicity was observed in this study, but none of the patients had received prior anthracycline therapy. Only one partial response of measurable disease was observed, all other patients had progressive disease on m-AMSA therapy. No significant clinical activity of m-AMSA against malignant melanoma was demonstrated in this very favorable group of patients.</description><identifier>ISSN: 0277-3732</identifier><identifier>PMID: 6896795</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Aminoacridines - adverse effects ; Aminoacridines - therapeutic use ; Amsacrine ; Drug Evaluation ; Female ; Humans ; Leukopenia - chemically induced ; Male ; Melanoma - drug therapy ; Middle Aged ; Nausea - chemically induced ; Neoplasm Metastasis ; Skin Neoplasms - drug therapy ; Vomiting - chemically induced</subject><ispartof>American journal of clinical oncology, 1982-08, Vol.5 (4), p.433</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6896795$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arseneau, J C</creatorcontrib><creatorcontrib>Wolter, J M</creatorcontrib><creatorcontrib>Probert, J C</creatorcontrib><creatorcontrib>Kuperminc, M</creatorcontrib><title>Phase II study of m-AMSA in advances malignant melanoma</title><title>American journal of clinical oncology</title><addtitle>Am J Clin Oncol</addtitle><description>A phase II study of methanesulfonamide, N-(4-(9 acridinylamino)-3-methoxyphenyl)-(m-AMSA) was undertaken by the Eastern Cooperative Oncology Group. Thirty-five evaluable patients were studied, 18 of whom had had no prior therapy and eight of whom had been treated only one cytotoxic drug. Thirty-one of these patients were ECOG performance status 2 or better. The dose of m-AMSA employed in this study was 40 mg/M2 as an I.V. infusion over 20 minutes daily for 3 days, repeated every 3 weeks. Leukopenia was found to be dose-limiting; thrombocytopenia and anemia were also observed. Other prominent toxicities included anorexia, nausea, and vomiting. No cardiovascular toxicity was observed in this study, but none of the patients had received prior anthracycline therapy. Only one partial response of measurable disease was observed, all other patients had progressive disease on m-AMSA therapy. No significant clinical activity of m-AMSA against malignant melanoma was demonstrated in this very favorable group of patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Aminoacridines - adverse effects</subject><subject>Aminoacridines - therapeutic use</subject><subject>Amsacrine</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Humans</subject><subject>Leukopenia - chemically induced</subject><subject>Male</subject><subject>Melanoma - drug therapy</subject><subject>Middle Aged</subject><subject>Nausea - chemically induced</subject><subject>Neoplasm Metastasis</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Vomiting - chemically induced</subject><issn>0277-3732</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1982</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotjstKAzEUQLNQaq1-gpAfCFzzupnlUHwMtCjYfblpbnRkMh2aVujfK9jVgbM4nCsxB42oDBp9I25r_QYA5wFnYuZD47Fxc4HvX1RZdp2sx1M6y32WRbXrj1b2o6T0Q-OOqyw09J8jjUdZeKBxX-hOXGcaKt9fuBCb56fN8lWt3l66ZbtSkzNONdYmAsYE1nOO1gQLkYMjBK0NBhchP7LPfwbIcN45HZwG7aIPyF6bhXj4z06nWDhtp0Nf6HDeXv7NL-G-PkU</recordid><startdate>198208</startdate><enddate>198208</enddate><creator>Arseneau, J C</creator><creator>Wolter, J M</creator><creator>Probert, J C</creator><creator>Kuperminc, M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>198208</creationdate><title>Phase II study of m-AMSA in advances malignant melanoma</title><author>Arseneau, J C ; Wolter, J M ; Probert, J C ; Kuperminc, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p535-944da0e7d046efb43840be85a70223785b0f1e6f85a0a3efc52852025b687e623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1982</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aminoacridines - adverse effects</topic><topic>Aminoacridines - therapeutic use</topic><topic>Amsacrine</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Humans</topic><topic>Leukopenia - chemically induced</topic><topic>Male</topic><topic>Melanoma - drug therapy</topic><topic>Middle Aged</topic><topic>Nausea - chemically induced</topic><topic>Neoplasm Metastasis</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Vomiting - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arseneau, J C</creatorcontrib><creatorcontrib>Wolter, J M</creatorcontrib><creatorcontrib>Probert, J C</creatorcontrib><creatorcontrib>Kuperminc, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>American journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arseneau, J C</au><au>Wolter, J M</au><au>Probert, J C</au><au>Kuperminc, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II study of m-AMSA in advances malignant melanoma</atitle><jtitle>American journal of clinical oncology</jtitle><addtitle>Am J Clin Oncol</addtitle><date>1982-08</date><risdate>1982</risdate><volume>5</volume><issue>4</issue><spage>433</spage><pages>433-</pages><issn>0277-3732</issn><abstract>A phase II study of methanesulfonamide, N-(4-(9 acridinylamino)-3-methoxyphenyl)-(m-AMSA) was undertaken by the Eastern Cooperative Oncology Group. Thirty-five evaluable patients were studied, 18 of whom had had no prior therapy and eight of whom had been treated only one cytotoxic drug. Thirty-one of these patients were ECOG performance status 2 or better. The dose of m-AMSA employed in this study was 40 mg/M2 as an I.V. infusion over 20 minutes daily for 3 days, repeated every 3 weeks. Leukopenia was found to be dose-limiting; thrombocytopenia and anemia were also observed. Other prominent toxicities included anorexia, nausea, and vomiting. No cardiovascular toxicity was observed in this study, but none of the patients had received prior anthracycline therapy. Only one partial response of measurable disease was observed, all other patients had progressive disease on m-AMSA therapy. No significant clinical activity of m-AMSA against malignant melanoma was demonstrated in this very favorable group of patients.</abstract><cop>United States</cop><pmid>6896795</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-3732 |
| ispartof | American journal of clinical oncology, 1982-08, Vol.5 (4), p.433 |
| issn | 0277-3732 |
| language | eng |
| recordid | cdi_pubmed_primary_6896795 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Aged Aminoacridines - adverse effects Aminoacridines - therapeutic use Amsacrine Drug Evaluation Female Humans Leukopenia - chemically induced Male Melanoma - drug therapy Middle Aged Nausea - chemically induced Neoplasm Metastasis Skin Neoplasms - drug therapy Vomiting - chemically induced |
| title | Phase II study of m-AMSA in advances malignant melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A00%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20study%20of%20m-AMSA%20in%20advances%20malignant%20melanoma&rft.jtitle=American%20journal%20of%20clinical%20oncology&rft.au=Arseneau,%20J%20C&rft.date=1982-08&rft.volume=5&rft.issue=4&rft.spage=433&rft.pages=433-&rft.issn=0277-3732&rft_id=info:doi/&rft_dat=%3Cpubmed%3E6896795%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/6896795&rfr_iscdi=true |